Vaccines

HPV vaccines

Value pack for a HPV vaccine
Payer value deck update for HPV
Literature review of epidemiology and economic data in HPV
Systematic literature review on the indirect protection from the HPV vaccination
HTA submission for a HPV vaccine
Cost-effectiveness analysis of a HPV vaccine for Spain
Manuscripts on the German and Spanish cost-effectiveness analysis of a HPV vaccine
Brief adaptation of a Markov model for a HPV vaccine
Update of a budget impact model for a HPV vaccine
Analysis and reporting on the budget impact of a HPV vaccine
Training sales reps on an interactive model for a HPV vaccine
Update to European one-pager value communication tool for a nine-valent HPV vaccine
One-pager communication tool on cross-protection in HPV
Revision of one-pagers in HPV vaccines
e-v@luate platform for HPV vaccines
Evidence package (literature review and value messages) for HPV vaccination
Development of a rationale for the need for a HPV vaccine
Development of an evidence compendium for HPV-related head and neck cancers
One-pager value communication on discounting approaches to HPV vaccination
One-pager on HPV-related head and neck cancer
Global value dossier modules for HPV vaccination cohorts
Anthropological study on the impact of HPV-related diseases
Manuscript on a HPV vaccine acceptance study in middle aged persons
HPV vaccination impact model in infectious diseases
HPV dossiers workshops and value message development
Targeted literature review on a HPV vaccine to support development of a payer value deck and e-v@luate platform
Value communications development and strategic consultancy for HPV communication strategy
Value communications support and manuscript on the burden of HPV-related diseases in men globally
Workshop on an alternative dosing schedule in HPV
Global value dossier on an alternative dosing schedule in HPV

Influenza vaccines

Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
Communications package for an influenza vaccine
Communication of the economics of an influenza vaccine
Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
Review of influenza vaccine uptake data
Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
Economic evaluation of a workplace influenza vaccination in Russia
Cost-effectiveness analysis of an influenza vaccine
Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
Adaptation of an influenza vaccine model to Belgium
Regulatory support for the validation of a questionnaire for influenza vaccination

Other vaccines

One-pager value communication tool for the measles, mumps and rubella (MMR) vaccine
Development of an e-v@luate EVIDENCE platform for a vaccines portfolio
Payer material development for vaccines in hepatitis A, rotavirus gastroenteritis (RVGE), shingles and varicella
Payer value slides for a varicella vaccine
Payer value deck for an MMR and varicella vaccine
Payer communications on a herpes zoster vaccine
e-v@luate platform on vaccines for HPV, varicella, MMR, shingles, hepatitis A and rotavirus
Payer slide deck to support HE models in dengue fever
Payer value deck update for a rotavirus vaccine
Estimating the return on investment from investing in adult immunisation in Europe
Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
Payer value deck in adult rotavirus gastroenteritis
Payer value deck on the humanistic burden of rotavirus
Manuscript, economic model and literature review on the burden of rotavirus and the impact of vaccination on health care utilization in Europe
Value communications support and manuscript on parental attitudes and knowledge of the varicella vaccination in Sweden
Global value dossier on dengue fever
Structured literature review and value strategic insight to understand the prevalence and burden of vaccine-preventable diseases (haemophilus influenzae, hepatitis A & B, HPV-associated cancers, influenza, measles, mumps, rubella, meningococcal disease, pneumonia, tetanus, diphtheria, whooping cough, chicken pox, and shingles) amongst sub-populations identified in the ACIP recommendations
Clinical outcome assessment (COA) landscape review and literature review in a vaccine for respiratory bacterial infections

Pneumococcal vaccines

Manuscripts on the health economics of a pneumococcal vaccine
Manuscripts on a vaccine for pneumococcal disease
Payer communications on a vaccine for pneumococcal disease
Responses to payer questions update on a pneumococcal disease vaccine
Payer value deck update for a pneumococcal disease vaccine
Payer material development on a pneumococcal disease vaccine
Update to a one-page value proposition on a pneumococcal disease vaccine
ev@luate platform for vaccine franchises in pneumococcal disease
Payer resources (payer value deck, FAQs and one-pager) for a pneumococcal vaccine
Payer value deck in adult pneumococcal disease (pneumococcal conjugate vaccination)